Skip to main content

Multaq FDA Approval History

FDA Approved: Yes (First approved July 1, 2009)
Brand name: Multaq
Generic name: dronedarone
Dosage form: Tablets
Company: Sanofi-aventis
Treatment for: Atrial Fibrillation, Atrial Flutter

Multaq (dronedarone) is antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter.

Development timeline for Multaq

DateArticle
Jul  2, 2009Approval FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter
Mar 19, 2009FDA Advisory Committee Recommends Approval of Multaq (dronedarone)
Aug  8, 2008Multaq (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation

See also

Multaq (dronedarone) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer